A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)
Dianthus Therapeutics
36 participants
Sep 17, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
* Day 1: IV loading dose * Week 1 to Week 15: Claseprubart administered SC every 2 weeks
* Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks
Locations(41)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06537999